DNA sequencing
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
NCT07084311
Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation
Phase: Phase 1/2
Role: Collaborator
Start: Oct 24, 2024
Completion: Nov 30, 2026
Loading map...